Home/ Stocks/ RAPP

Rapport Therapeutics, Inc. Common Stock

RAPP XNAS

$45.49 -0.86 (-1.86%) ▼ 15-min delayed

Open

$47.00

High

$48.00

Low

$44.91

Volume

246.1K

Market Cap

$2.22B

About Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 84 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-56,615,000	$-1.19
Q1 2026	$20.00M	$-19,857,000	$-0.42
FY 2025	$0	$-111,483,000	$-2.86
Q3 2025	$0	$-26,925,000	$-0.71

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for RAPP yet. Check out our latest market news or earnings calendar.

Get RAPP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Rapport Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.